Ricerc@Sapienza

COVID-19 is imposing unprecedented stress on our healthcare system but in some cases these
changes, such as more telemedicine for pain management, may be valuable paradigm shifts that shape the future of modern medicine. Pain does not stop for the pandemic and pain care must continue as well.

We read with great interest the study by Clementi et al.
that would like to explore the efcacy of a single intraarticular
injection of ultra-high molecular weight hyaluronic
acid in patients with hip osteoarthritis. Actually, we
believe that investigating just patients’ clinical status using
VAS and WOMAC scale should have been supported by
further information. In fact, in order to have more data that
could infuence the recent clinical practice, it is important to
consider also  the efect that the intra-articular injection of

Background Approximately two-thirds of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) need long-term intravenous immunoglobulin. Subcutaneous immunoglobulin (SCIg) is an alternative option for immunoglobulin delivery, but has not previously been investigated in a large trial of CIDP. The PATH study compared relapse rates in patients given SCIg versus placebo. Methods Between March 12, 2012, and Sept 20, 2016, we studied patients from 69 neuromuscular centres in North America, Europe, Israel, Australia, and Japan.

Despite decades of research on neurobiological mechanisms of psychostimulant addiction, the only effective treatment for many addicts is contingency management, a behavioral treatment that uses alternative non-drug reward to maintain abstinence. However, when contingency management is discontinued, most addicts relapse to drug use. The brain mechanisms underlying relapse after cessation of contingency management are largely unknown, and, until recently, an animal model of this human condition did not exist.